Sultan Sherif, Acharya Yogesh, Hazima Mohiey, Salahat Hiba, Parodi Juan Carlos, Hynes Niamh
Western Vascular Institute, Department of Vascular and Endovascular Surgery, University Hospital Galway, National University of Ireland, Newcastle Road, Galway H91 YR71, Ireland.
Department of Vascular and Endovascular Surgery, Galway Clinic, Doughiska, Royal College of Surgeons in Ireland and the National University of Ireland, Galway Affiliated Hospital, Ireland.
Eur Heart J Case Rep. 2021 Sep 15;5(10):ytab339. doi: 10.1093/ehjcr/ytab339. eCollection 2021 Oct.
Thoracic and abdominal aortic stent grafts are firmer and more rigid than the native aorta. Aortic implanted devices have been implicated in the development of acute systolic hypertension, elevated pulse pressure, and reduced coronary perfusion.
We report four cases of staged thoracic endovascular aortic repair (TEVAR) and then endovascular aneurysm repair (EVAR). All patients had TEVAR first for thoracic aortic aneurysm and later on developed infra-renal abdominal aortic aneurysm (AAA) that required EVAR. There were three males and one female with a median age of 74.5 years (range 67.5-78.5). None of the patients developed aortic-related major clinical adverse effects or required any aortic intervention during their follow-up. However, within 2 years, all patients developed symptomatic left ventricular hypertrophy with diastolic dysfunction. All patients had bilateral lower limb oedema, with on and off chest pain and shortness of breath (SOB), necessitating coronary angiograms, which showed no evidence of coronary artery disease. Three patients died from cardiovascular-related morbidities, and the fourth patient is still complaining of SOB despite a normal coronary angiogram.
Aortic-endograft compliance mismatch is an invisible enemy, with troubling consequences for the aorta proximal and distal to the endograft. Aortic stiffness due to vascular endograft could lead to cardiovascular adverse events, even in the absence of direct aortic-related complications. After combined TEVAR and EVAR, the compliance mismatch and elasticity loss are even more pronounced than with TEVAR alone, which necessitates patient monitoring for the development of cardiovascular complications.
胸主动脉和腹主动脉覆膜支架比天然主动脉更硬更刚。主动脉植入装置与急性收缩期高血压、脉压升高及冠状动脉灌注减少的发生有关。
我们报告4例分期进行胸主动脉腔内修复术(TEVAR)然后行腹主动脉瘤腔内修复术(EVAR)的病例。所有患者均先因胸主动脉瘤接受TEVAR,随后出现肾下腹主动脉瘤(AAA),需要进行EVAR。有3名男性和1名女性,中位年龄为74.5岁(范围67.5 - 78.5岁)。所有患者在随访期间均未出现与主动脉相关的重大临床不良反应,也无需进行任何主动脉干预。然而,在2年内,所有患者均出现有症状的左心室肥厚伴舒张功能障碍。所有患者均有双侧下肢水肿,伴有间断胸痛和气短(SOB),因此需要进行冠状动脉造影,结果显示无冠状动脉疾病证据。3例患者死于心血管相关疾病,第4例患者尽管冠状动脉造影正常,但仍诉说有气短症状。
主动脉移植物顺应性不匹配是一个无形的敌人,对内植物近端和远端的主动脉都会产生不良后果。即使没有直接的主动脉相关并发症,血管内移植物导致的主动脉僵硬也可能引发心血管不良事件。在联合进行TEVAR和EVAR后,顺应性不匹配和弹性丧失比单独进行TEVAR时更为明显,这就需要对患者进行监测,以发现心血管并发症的发生。